Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

The US Food and Drug Administration (FDA) has expanded emergency use authorisation (EUA) for Thermo Fisher Scientific‘s Applied Biosystems TaqPath Covid-19 test kit.

The multiplex real-time PCR test can be used for the qualitative detection of nucleic acid from SARS-CoV-2 virus, which causes Covid-19.

The test initially received EUA on 13 March, which was subsequently expanded last month. The third expansion increases the number of high-throughput PCR instruments that labs can use to run tests.

Additionally, it offers improved flexibility in testing workflows by providing new options for reagents and consumables used in sample preparation and extraction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The expanded EUA also adds the company’s MagMAX viral/pathogen II nucleic isolation kit as an alternative to increase the availability of RNA extraction reagents. Moreover, the updated sample purification step enables a variety of microplate options.

Thermo Fisher Scientific president, chairman and CEO Marc Casper said: “Increasing Covid-19 testing is a top priority in re-opening global economies.

“With this expanded authorisation, additional instrumentation can be brought online in labs around the world and the number of tests they can run will increase, which will help to support the need for more testing as people start returning to work.”

The labs can now run tests on specific configurations of QuantStudio 7 Flex and QuantStudio 5 Real-time PCR instruments, in addition to the previously approved Applied Biosystems 7500 Real-time PCR series and a version of the Applied Biosystems QuantStudio 5.

This significantly increases the number of instruments available for testing.

Last month, the company launched AcroMetrix Coronavirus 2019 (Covid-19) RNA Control to monitor and validate Covid-19 molecular diagnostic tests.